Bryan J. McMichael - 22 Jan 2026 Form 4 Insider Report for Coherus Oncology, Inc. (CHRS)

Reporting relationship: Chief Financial Officer
Issuer ticker: CHRS
Reported as of: 22 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jan 2026, 16:39:43 UTC
Prior SEC filing: 22 Jan 2026
Next SEC filing: 02 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Bryan J. McMichael

Key filing fact

Bryan J. McMichael filed Form 4 for Coherus Oncology, Inc. (CHRS) on 26 Jan 2026.

Key facts

This page summarizes Bryan J. McMichael's Form 4 filing for Coherus Oncology, Inc. (CHRS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Jan 2026, 16:39.

Change

Previous filing in this sequence was filed on 22 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001944868 Primary reporting owner

McMichael Bryan J

Relationship: Chief Financial Officer
Address: C/O COHERUS ONCOLOGY, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY
Signature: /s/ Bryan J. McMichael
Signature date: 26 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CHRS transaction

Common Stock

Award

Transaction value: $0
Shares: +112,500
Change %: +530%
Price: $0.000000
Shares after: 133,736
Date: 22 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CHRS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +225,000
Change %
Price: $0.000000
Shares after: 225,000
Date: 22 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 225,000
Exercise price: $1.59
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest on May 20, 2027 and 50% of the RSUs vest on March 20, 2029, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Footnote F2

The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 22, 2026 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.